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ABSTRACT 
Nanotechnologies have a more attention in recants researches. It has more advantages over other technologies. New physical technologies and 
properties both at the same time in sample preparation and device fabrication evoke on account of the development. There is an exponential 
interest in the development of novel drug delivery systems with the help of nanoparticles. Solid lipid nanoparticles are aqueous colloidal 
dispersion of matrix. In this matrix is made up of biodegradable lipids. Various researchers are involved in this field because of its attention in 
the industry. There are many methods high shear homogenization, ultrasonication, Microemulsion, Solvent emulsification and diffusion method 
and solvent evaporation technique, double emulsion method, film ultrsound diffusion method etc. Solid Lipid Nanoparticles has the size ranges 
from 1 to 1000 nm particles can use for drug delivery system. Solid Lipid Nanoparticles with Beta blocker drugs gives us a big advantage over 
conventional drug delivery is to improve therapeutic efficacy and sustained drug release properties while overcoming the problems like poor 
solubility and low oral bioavailability of beta blocker drugs. Beta blocker drugs possess some drawbacks like low bioavailability, relatively short 
half-life, low permeability, and adverse side effects. For effective delivery of these beta blocker drugs, drug delivery systems are used to provide 
an alternative strategy to administer these agents with improved bioavailability and therapeutic effects of the beta blocker. 
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Nanotechnology is a knowledge which comes from the fields 
of physics, chemistry, biology, materials science and health 
sciences. Nanotechnology has lots of applications in almost 
all field of science. Nanoparticles is defined as particulate 
dispersions with the size range of 10-1000nm. The drug is 
then dissolved, entrapped and encapsulated to a 
Nanoparticles matrix. [1] Nanotechnology is used to improve 
bioavailability of certain drugs in which the difference when 
compared to the conventional system has been found to be 
very much. An in vivo study of nanoparticles was found to 
have increased in bioavailability. [2] Delivery of a drug 
molecule to specific sites is the challenge for research areas 
in pharmaceutical sciences. By developing colloidal delivery 
systems like nanoparticles, new frontiers have opened for 
improving drug delivery. Nanoparticles with the special 
characteristics like small particle size, massive surface area 
and the capability of adjusting by changing the surface 
properties have numerous advantages over other delivery 
forms. [3] 
Nowadays a significant effort has been made to develop 
nanotechnology for drug delivery, because of its advantage 
like it offers a suitable means of delivering small molecular 
weight drugs. Solid lipid Nanoparticles is an alternative drug 
delivery system to colloidal drug delivery systems like lipid 
emulsions, liposomes etc. SLN combines the advantages of 
different colloidal carriers and also treat some of their 
disadvantages. SLN is uses to improve the bioavailability of 
drug. Tablet gives us the lowest cost approach to dosage 
forms.  Matrix tablets is an important tool for oral release 
dosage forms. [4] 
MATRIX TABLETS 
Advantages of Matrix Tablets: [5], [6] 
 Easy for manufacturing 
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 Versatile and effective with low cost  
 Made to release high molecular weight molecules  
 By using conventional processes and equipment 
Product based on matrix design can be manufactured. 
 Dose dumping and the toxic effects are reduced due to 
high plasma concentration.  
 They give Better control of therapeutic drug 
concentration. 
 They improve the bioavailability of some drugs. 
 They increase the stability of drug by protecting them 
from hydrolysis or other derivative changes in the 
gastrointestinal tract.  
Disadvantages of the matrix tablet: [5] 
 Necessity to remove the remaining matrix after the 
release of drug. 
 Rates of the drug release may vary with the square 
root of time.  
 Matrix tablet lack flexibility. 
Rationale of developing matrix devices: [5] 
 To broaden the duration of action of the drug. 
 To reduce the frequency of dosing. 
 To reduce inter and intra subject variability. 
 To minimize the fluctuations in plasma level. 
 To improve drug utilization. 
 To reduce adverse effects. 
Types of matrix systems:  
The matrix system can be divided into five categories 
depending on the types of retarding agents or polymeric 
materials.  
1. Hydrophobic matrix systems: 
In this matrix system the primary rate-controlling 
components of the hydrophobic matrix are water-insoluble 
in nature. Waxes, glycerides, fatty acids, and polymeric 
materials such as ethyl cellulose, Methyl Cellulose and 
acrylate copolymers like ingredients are used. To alter drug 
release, it may be necessary to incorporate soluble 
ingredients like lactose into the formulation. The presence of 
an insoluble ingredient in the formulations helps to balance 
the physical dimension of the hydrophobic matrix while the 
drug is release. The diffusion of the active ingredient is the 
release mechanism and corresponding release characteristic 
can be described by Higuchi kinetic model. Hydrophobic 
matrix provides programmable rates of delivery, which have 
become more important. Constant rate delivery has been 
one among the primary targets. It is used especially for a 
drug with narrow therapeutic index. [7] 
2. Hydrophilic matrix system: 
In this the primary rate-limiting ingredients of hydrophilic 
matrix are polymers that would work well when comes in 
contact with the aqueous solution, form a gel layer on the 
surface of the system. When the release medium i.e. water is 
compatible with a polymer then the solvent penetrates into 
the free spaces between macromolecular chains. Polymer 
may undergo a relaxation process, because of the stress of 
the penetrated solvent so the polymer chains become more 
flexible and the matrix swells. This allows the encapsulation 
of a drug to diffuse more rapidly out of the matrix. It would 
take more time to diffuse out of the matrix when the matrix 
swelling lengthens the diffusion path. It has been widely 
known for swelling and diffusion, which are not the only 
factors that determine the rate of drug release. For 
dissolvable polymer matrix, dissolution is another important 
mechanism that can modulate the drug delivery rate. While 
swelling, dissolution can be the predominant factor for a 
specific type of polymers. The drug release kinetics is a 
combination of these two mechanisms. The increase 
mobility of polymeric chain gives the transport of dissolved 
drug. [7] 
Different factors effecting rate drug release from matrix 
systems:  
The release of drug from polymer matrix is dependent upon 
the physicochemical properties of drug and polymer and it is 
also dependent on several biological parameters  
1. Swelling property of polymer: 
Polymer dissolution including adsorption of water in more 
accessible places that rupture the polymer-polymer linking 
with the simultaneously form water-polymer linking, 
separation of polymeric chains, swelling. Finally, dispersion 
of polymeric chain in dissolution medium is done which 
indicates study of polymer hydration process for the 
polymers is required.[8] 
2. Drug solubility: 
Molecular size and water solubility of the drug are 
determinants in the release of drug which is from swelling 
and erosion of controlled polymeric matrices. For the drugs 
with reasonable aqueous solubility, the release of drugs 
occurs by dissolution medium and for drugs with poor 
solubility, release occurs by dissolution of drug particles 
through erosion of the matrix tablet. [9] 
3. Solubility: 
In vivo sink condition maintained actively by hem perfusion, 
it is logical that all the in vitro drug release studies should 
also be conducted under perfect sink condition. [8] 
4. Drug loading dose: 
Effect of initial drug loading of the tablets on the resulting 
release kinetics is more complex with poorly water soluble 
drugs which further increase the initial drug loading. The 
relative release rate first decreases and then increases 
where the absolute release rate increases. While the amount 
of drug present at a certain position in the matrix exceeds 
the amount of drug soluble and the excess of drug has to be 
considered as non-dissolved. [9] 
5. Additives: 
Effect of adding non-polymeric excipients to a polymeric 
matrix has been claimed to produce an increase in the 
release rate of hydro soluble active principles. [8] 
6. Dose size: 
In this there is an upper limit to the bulk size of the dose to 
be administered. Compounds which requires large dose size 
can sometimes be given in multiple amounts or formulated 
into liquid systems. Another consideration is the margin of 
safety involved in the administration of a large amount of a 
drug with a narrow therapeutic range. [8] 
 
Nagargoje et al                                                                                              Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):1078-1084 
ISSN: 2250-1177                                                                                  [1080]                                                                                    CODEN (USA): JDDTAO 
Mechanism of Drug Release from Matrix System:  
1) Diffusion method: 
In this method the outside layer of the drug is exposed to the 
bathing solution is dissolved first and then diffuses out of the 
matrix. This method continues with the interface between 
the bathing solution and the solid drug which moves 
towards the interior. It follows for this system to be diffusion 
controlled. The rate of dissolution of drug particles in matrix 
must be much faster than the diffusion rate of dissolved drug 
while leaving the matrix. [5] 
Derivation of the mathematical model to describe this 
system involves following assumption:  
Pseudo steady state is maintained while the drug is releases. 
Drug particles have diameter less than the average distance 
of the drug diffusion through the matrix. Bathing solution 
gives us the sink condition at all times. [10] 
If a system is diffusion controlled then it is expected that a 
plot of drug release vs. square root of time then the result 
will come in straight line. When the drug is release from a 
porous matrix it involves simultaneous penetration of 
surrounding liquid, dissolution and leaching of the drug 
through winding interstitial channels. The volume and 
length of the openings must be noted for the drug release 







       










Where, p is Porosity of the matrix, 
 t is Tortuosity,  
Ca is solubility of the drug in the release medium, 
Ds is Diffusion coefficient in the release medium 
and  
T is Diffusional path length. 
For pseudo steady state, the equation can be written as:  
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The total porosity of the matrix can be calculated with the 
following equation: 
                ⁄⁄  
Where, p is Porosity,  
ρ is Drug density, 
Pa is Porosity due to air pockets in the matrix, 
ρ ex is Density of the water soluble excipients and 
C ex is Concentration of water soluble excipient. [5] 
Higuchi model: 
The drug release from Higuchi model is slower than zero 
order profile. When a matrix tablet is placed in the 
dissolution medium the initial release occurs from the tablet 
superficial layer and the release rate is fast. When time 
passes the external layers of the tablet become depleted of 
the drug and water molecule must travel through long 
channels to reach the drug which remains into the tablet. [10] 
Similarly when the drug solution is formed in the tablet, it 
must diffuse through long capillaries to reach the external 
dissolution medium. The reason for continuous decrease in 
rate of the drug release is more than for the matrix swells. 
When the longer is the diffusion path length then it requires 
for the drug to come out longer. [5] 
        
Where, Q is Fraction of drug release in time (t), 
t is Time, 
k is Rate constant (incorporates characteristics of 
polymer system and drug) and 
n is Diffusional exponent [5] 
CLASSIFICATION OF MATRIX TABLET 
1. Hydrophobic matrices: 
The concept of using hydrophobic material as matrix tablet 
was first introduced in 1959. This method is very popular as 
in this method to obtain an oral dosage form, then the drug 
is mixed with a hydrophobic polymer and at that time then it 
compressed to a tablet. Drug released is obtained because 
the dissolving drug is diffused through channels which exist 
between compacted polymer particles. Hydrophobic 
matrices are the only system into which the use of polymer 
isn’t essential for providing drug release, when insoluble 
polymers have been used. Primary rate controlling 
component of hydrophobic matrix are water insoluble in 
nature like waxes, glycerides and polymeric materials such 
as methyl cellulose, ethyl cellulose to modulate the release 
rate of drug. [11] 
2. Lipid matrices: 
These matrices were prepared by lipid waxes and related 
materials. Drug release from such material occurs through 
pore diffusion and erosion. Release characteristic are then 
more sensitive to digestive fluid composition than to totally 
insoluble polymer matrix. [12] 
3. Hydrophilic matrix tablets:  
Hydrophilic matrix is presently one of the most interesting 
drug delivery systems which are most widely used to control 
the release rate of drugs with their flexibility to obtain 
desirable both drug release profile and broad regulatory 
acceptance. It defined as a Homogeneous dispersion of drug 
molecules within a skeleton of hydrophilic polymers which 
can swells upon contact with water. These systems are 
known as swellable-controlled release systems. When the 
release rate is observed it can be the zero-order release. 
Most hydrophilic matrices are obtained by compression. [13] 
4. Biodegradable Matrices:  
These consist of the polymers which then comprised of 
monomers linked to each other by functional groups which 
further have unstable linkage in the backbone. It is degraded 
by enzymes which are generated by surrounding living cells 
in oligomers that can be metabolized or excreted. Examples 
are natural polymers like proteins, polysaccharides and 
modified natural polymers, synthetic polymers such as 
aliphatic poly and poly anhydrides.[13] 
5. Mineral Matrices:  
These include polymers which are obtained from various 
species of seaweeds. Example: Alginic acid which is a 
hydrophilic carbohydrate obtained from species of brown 
seaweeds by the use of dilute alkali.[5],[13] 
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NANOPARTICULATE DRUG DELIVERY  
Rationale for using Nanoparticles for oral drug delivery: 
Drug with low aqueous solubility and low permeability (i.e. 
BCS class II, III, IV drugs) are difficult to deliver by oral 
route. The difficulty arises due to varying GI pH and low 
bioavailability. [14] 
This wide difference in the pH can severely hamper the 
pharmacological activity of the drug Oral bioavailability of 
some is affected as they undergo chemical degradation at 
acidic pH. Different liver Enzymes cause significant 
degradation of antihypertensive drugs Intestinal mucosa is 
the other barrier which cause obstacle to drug permeation.  
Gastric mucosal barrier includes extrinsic barrier and 
intrinsic barrier. Tight junction between two cells make 
intrinsic barrier. There are different mechanisms by which 
any molecule can cross the barrier viz. transcytosis, 
paracellular and transcellular. Being an active transport 
pathway, transcytosis restricts charged molecules and 
molecules with large size. [15] 
Mucoadhesive formulations can be formulated to overcome 
the intestinal barrier so to increase time of contact with 
mucus and increases the drug concentration at the site of 
drug absorption. Some mucoadhesive agents have the 
property of enhancing the permeation by Paracellular occurs 
due to opening the tight junction. Another approach to 
enhance GI permeability is by carrying out transport of drug 
molecule through M cells possessing lesser quantity of 
protease enzyme and also lacks mucus secretion. [16]  
Solid Lipid nanoparticles (SLN) and Nanostructured lipid 
carriers (NLC) can be transferred by clathrin-mediated 
transport through intestinal barrier. Solid Lipid 
nanoparticles can be transferred using trnscytosisis by 
caveolae-mediated endocytosis and Nanostructured lipid 
carriers can be transported through tight junctions of cells 
by means of paracellular transport [17] 
Nanoparticulate systems like nanoemulsion, liposome, Solid 
Lipid nanoparticles and Nanostructured lipid carriers have 
been found to surpass first-pass metabolism by means of 
lymphatic transport. Charge present on the nanoparticles 
affects Lymphatic update and hence negatively charged 
particles exhibits higher lymphatic uptake. [18] Efflux 
transporter such as P-glycoprotein located on the intestinal 
wall promotes efflux of some of antihypertensive causing 
poor oral bioavailability of these drugs. [19] Such difficulties 
can be avoided and along with this, sustained release for 
dose and administration frequency reduction can be 
achieved by encapsulating drug in nanoparticles. [20] 
A. SOLID LIPID NANOPARTICLES 
Aim for preparation of Solid lipid nanoparticles: 
 Increased drug stability. 
 High drug pay load. 
 No toxicity of carrier.  
 Avoidance of organic solvents. 
 Incorporation of lipophilic and hydrophilic drug 
matrix. [21] 
Method for preparation of solid lipid Nanoparticles:  
1. High pressure homogenization: 
It pushes the liquid down with high pressure at hollow gap 
of some few microns which are nearly 100Km/h rate and 
with high viscosity the fluid accelerates to a very short 
distance. Very high-pressure stress force interrupts the 
particle down to submicron size range with 5-40% lipid 
content. There are two homogenization methods (A) hot 
homogenization (B) Cold homogenization method which are 
used for the production of SLN. [21] 
a) Hot homogenization:  
This is an emulsion which can be carried out in above the 
melting point of the liquid. With this of high share mixing 
device, a pre-emulsion of the drug loaded lipid melt and the 
aqueous emulsifier phase is obtained has a same 
temperature. The HPH of pre emulsion can be carried out on 
the above liquid melting point. Because of the decrease 
viscosity of inner phase of emulsion in high temperature, 
particle size would be lower. With the Increase in the 
homogenization pressure or the number of cycles increases 
the particle size due to high kinetic energy of the particles. 
[21] 
b) Cold homogenization:  
This has been developing to over-come the temperature 
related degradation problems, loss of drug in the aqueous 
phase and partitioning associated with hot homogenization 
method. Due to complexity of the crystallization step of the 
nano emulsion resulting in several modifications and super 
cooled melts, leads to Unpredictable polymeric transitions of 
the lipid. Here, drug is incorporated in melted lipid and the 
lipid melt is cooled rapidly using dry ice or liquid nitrogen. 
The solid material is ground by a mortar mill. The prepared 
lipid nanoparticles and micro particles are then dispersed in 
a cold emulsifier solution at or below room temperature. 
The temperature should be regulated to ensure solid state of 
the lipid during homogenization.  However, compared to hot 
homogenization, larger particle sizes and a broader size 
distribution are typical of cold homogenization sample. [21] 
Advantages: 
 It has a Low capital cost. 
 It demonstrated at lab scale. [22] 
Disadvantages:   
 Energy intensive process.  
 Poly disperses distributions. [22] 
2. Solvent Evaporation method: 
In this method drug which is lipophilic in nature is dissolved 
into a water-immiscible organic solvent and it is then 
emulsified in an aqueous phase which contains the 
surfactant under continuous stirring of magnetic stirrer.  
The organic solvent was then evaporated and 
nanoparticulate dispersion is formed by precipitation of the 
lipid. [21] 
Advantages: 
 It is Scalable. 
 It has mature technology.  
 It is a continuous process.  
 It commercially demonstrated. [22] 
Disadvantages: 
 It is extremely energy intensive process.  
 It has poly disperses distributions.  
 It causes bimolecular damage.[22] 
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3. Micro emulsion-based method: 
This method is based on dilution of microemulsions. 
Microemulsions are two-phase systems made up of an inner 
and outer phase. They are made by stirring an optically 
transparent mixture, which typically composed of a low 
melting fatty acid. The hot microemulsion is then dispersed 
in cold water (2-3°C) with stirring.  This dispersion can be 
used in this process as granulation fluid for transferring in to 
solid product (tablets, pellets) by granulation process but 
when in case of low particle content too much of water 
needs to be removed. High-temperature facilitates rapid 
lipid crystallization and it also prevents aggregation, because 
of the dilution step achievable lipid contents are lower 
compared with HPH based formulations. [21] 
Advantages:  
 It has a low mechanical energy input.  
 It has a theoretical stability. [22] 
Disadvantages:  
 It is extremely sensitive to change.  
 Labor intensive formulation work.   
 It has a low nanoparticles concentration.[22] 
4. Solvent emulsification method: 
In this technique, the solvent used are must be partially 
miscible with water. This technique is carried out either in 
aqueous phase or in oil phase. Both the solvent and water 
were mutually saturated in order to ensure the initial 
thermodynamic equilibrium of liquid. When heating is 
required to solubilize the lipid, then saturation step was 
performed at that temperature. Then the lipid and drug 
were dissolved in water saturated solvent and this organic 
phase was emulsified with solvent saturated solution 
containing stabilizer using mechanical stirrer. After the 
formation, water in typical ratio ranges from 1:5 to 1:10, 
were added to the system in order to allow solvent diffusion 
into the continuous phase, thus forming aggregation of the 
lipid in the nanoparticles. Here the phases were maintained 
at same elevated temperature and the diffusion step was 
performed either at room temperature or at the 
temperature, in which it is the lipid was dissolved. 
Throughout the process constant stirring was maintained. 
Lastly, the diffused solvent was eliminated by vacuum 
distillation.[21] 
5. Double Emulsion method: 
In double emulsion method a drug is encapsulated with 
stabilizer initially, which prevent the partitioning of drug in 
external water phase while solvent evaporation in the 
external water phase of double emulsion. [22] 
6. Film ultrasound dispersion:  
In this method the lipid and drug were put in suitable 
organic solution and after decompression, rotation and 
evaporation then lipid is formed. Then the solution including 
the emulsion was added. With the help of the ultrasound 
with the probe of diffuser, SLN with little and uniform 
particle size is formed.[22] 
Advantages of SLN: 
 The main Use of biodegradable physiological lipid 
matrix. It decreases the danger of acute and chronic 
toxicity production methods.[23] 
 It Improved bioavailability of poorly water soluble 
drugs. 
 It gives Target specific delivery of drugs which further 
enhanced drug penetration into the skin  
 It gives Protection to chemically labile agents from 
degradation and sensitive drugs from outer 
environment.  
 SLNs have better stability compared to liposomes  
 Enhance the bioavailability of entrapped bioactive and 
chemical production of labile incorporated com-pound. 
[4] 
 High concentration of compound.  
 Easy scale up is possible of solid lipid Nanoparticles. It 
gives good stability.[5] 
Disadvantages of SLN: 
 It has Poor drug loading capacity,[2, 3] 
 Drug expulsion after polymeric transition during 
storage  
 Relatively high water content of the dispersions [3] 
 It has some uncertain gelation tendency. [5] 
 Some of uneven kinetics for polymeric transition.  
 It shows some particle growth during storage.  
 Relatively higher water content of the dispersion.[5] 
Applications (For beta blockers delivery): 
 SLN for beta blockers are used to improve therapeutic 
efficacy and sustained drug release properties which 
overcomes the problems such as poor solubility and 
low oral bioavailability.[24] 
 SLN for beta blockers is also used to prevent high first-
pass metabolism.[22] 
 SLN for beta blockers are used to enhance onset of 
action of a drug.[24] 
 Beta blockers provides a promising approach for 
enhancing solubility.[22] 
 SLN for beta blockers are used to avoid chlorinated 
solvents, surfactants to minimize their toxic effects.[25] 
 Beta blockers are useful when combining multiple 
classes of antihypertensive drugs together that is one 
of the most important factors for achieving blood 
pressure control[26] 
 Most commonly SLN for beta blockers are also used to 
treat hypertension because β-blockers are potent and 
highly effective.[26] 
 Beta blockers are the quantum of their utilization to 
overcome this problem beta blocker is formed with 
SLN. 
 Beta blockers overloaded with nanoparticles are also 
used in ocular drug delivery.  [27] 
e.g. Venishetty VK (2012): [28] prepared carvedilol loaded 
Solid lipid nanoparticles coated with N-carboxymethyl 
chitosan. The main aim behind coating of SLN was to protect 
drug from releasing rapidly in acidic environment. For the 
preparation of SLN monoglycerides was used as lipid, and 
surfactant used was lecithin and charged modifier used was 
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stearylamine. Prepared uncoated SLN were then subjected 
to different evaluation parameters like crystallinity, 
determination of particle size, determination of zeta 
potential and entrapment efficacy and stability studies. After 
that coated SLN were characterized by zeta potential and 
analysis X-ray by Photon Spectroscopy. Drug release studies 
were carried out IN-vitro and in rats. Coating imparts 
enhanced bioavailability of carvedilol as compared to 
uncoated one.  
B. NANOSUSPENSIONS [29] 
Nanosuspension can be defined as colloidal dispersions of 
drug particles biphasic in nature and stabilized with the help 
of surfactants.  Particle size of dispersed phase is less than 
1 μm. Poorly water soluble drugs can be delivered due to 
nano size. Solid content of nanosuspension can be increased 
up to 40% so to reduce the size of dose and so to improve 
patient compliance nanosuspension can be converted into 
dosage forms. Like pellets or tablets, with the use of different 
methods like extrusion-spheronization and spray/ freeze 
drying.  
e.g. Thadkala et al. (2015) [30]: developed oral 
nanosuspension tablet of Nebivolol HCl for the improvement 
of dissolution rate and so the absorption. Nebivolol 
hydrochloride belongs to BCS Class II and is lipophilic in 
nature. Nebivolol nanosuspension was formulated using 
solvent displacement method. Optimized formulation 
showed maximum drug release than pure drug and followed 
first order release kinetics.   
C. DENDRIMERS[9] 
Dendrimers can be defined as highly branched polymeric 
carrier which are star-shaped macromolecules with 
dimensions in nanometers(1-100nm) Dendrimers have 
unique properties like narrow polydispersity index with 
controlled molecular structure and 3D structure. These are 
multivalent entity with multiple functional groups. 
Dendrimers consist of three domains –a core, branches and 
terminally attached functional group. Polymers used in 
dendrimers are polyamines, polyamidoamines, polyamides 
(polypeptides) and poly (aryl ethers). Most commonly used 
dendrimers are polyamidoamines.  Different genes, peptides 
and proteins can be delivered using Dendrimers. Also, they 
can be used for Immunoassay, gene therapy and 
solubilization purpose. Different antihypertensive drugs can 
be delivered by oral route successfully by conjugation and 
encapsulation within dendrimers which bypasses efflux 
transporter. Solubility improvement depends upon different 
factors like pH and concentration of dendrimers and, size of 
generation, temperature, core and terminal functionality .  
D'Emanuele A., et al., (2004): [31] carried out a study with the 
aim of solubility improvement of Propranolol. Propranolol 
was conjugated with lauroyl-G3. The formulated drug-
dendrimers conjugates showed enhanced solubility as 
compared to pure drug  
D. PROLIPOSOMES [29] 
Proliposomes are dry and free-flowing particles having a 
dispersed system. This dispersed system can be immediately 
converted into liposomal suspensions when come in contact 
with aqueous phase. Proliposomes are more advantageous 
in terms of drug absorption when compared with 
conventional liposomes. Solid properties of proliposomes 
make them physically more stable without any change in 
intrinsic properties, helps to improve solubility of different 
hydrophobic drugs. Kim et al. (2008): [32] developed 
proliposomes formulation for Propranolol for achieving 
sustained drug release Formulated proliposomes showed 
good micromeritics and flow properties. 
CONCLUSION  
Nanotechnology has a great potential for effective delivery of 
poorly soluble drugs with improving solubility and oral 
bioavailability. Most of the beta blockers can be delivered 
successfully at the site of absorption by using novel drug 
delivery systems with the incorporation of nanoparticles. 
Novel drug delivery system possesses numerous benefits in 
terms of improved bioavailability and so the therapeutic 
efficacy and improved targeting. Different NDDS with 
Nanoparticulate systems like solid lipid nanoparticles, 
dendrimers, nano-suspensions and proliposomes can be 
formulated into matrix tablets for successful delivery of beta 
blockers at site of absorption.SLN can enhance production 
scalability and improved drug targeting, while 
nanosuspension can improve water solubility of β blockers 
with their nano size. Multivalent and highly branched 
Dendrimers provide ease of binding, while proliposomes 
provide improved flow characteristics for beta blockers. 
Therefore, Matrix tablets of β-blockers with Nanoparticulate 
system can be successfully formulated. 
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